Maxpro Capital Acquisition, a blank check company targeting the healthcare and technology sectors, lowered the proposed deal size for its upcoming IPO on Monday.
The Taipei City, Taiwan-based company now plans to raise $90 million by offering 9 million units at $10. The company had previously filed to offer 10 million units at the same price. Each unit now consists of one share of common stock and one warrant, exercisable at $11.50. Each unit previously contained one-half of a warrant. At the revised deal size, Maxpro Capital Acquisition will raise -10% less in proceeds than previously anticipated.
The company is led by CEO and Chairman Moses Chen, who currently serves as Managing Director of Maxpro Ventures and previously served as Acting COO of SyneuRx International. The company plans to target the healthcare and technology sectors, as well as technologically advanced segments of the medical, biotechnology, digital, data and data science, industrial, and financial fields. It plans to focus on businesses with enterprise values between $200 million and $2 billion, initially prioritizing those in North America, Europe, and Asia.
Maxpro Capital Acquisition was founded in 2021 and plans to list on the Nasdaq under the symbol JMACU. EF Hutton is the sole bookrunner on the deal.
